Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: An analysis of pooled data from open-label long-term extension studies

RMD Open

Volumn 3, Issue 2, 2017, Pages

  Fleischmann, Roy ^a   Wollenhaupt, Jürgen ^b   Takiya, Liza ^c   Maniccia, Anna ^c   Kwok, Kenneth ^c   Wang, Lisy ^c   Van Vollenhoven, Ronald F ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF HAMBURG   (Germany)

^c PFIZER INC   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

disease activity; rheumatoid arthritis; treatment

Indexed keywords

GLUCOCORTICOID; TOFACITINIB;

ADULT; ARTICLE; BRONCHITIS; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL TRIAL; CROHN DISEASE ACTIVITY INDEX; CYTOMEGALOVIRUS INFECTION; DAS28; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; ESOPHAGUS CANDIDIASIS; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HERPES ZOSTER; HUMAN; HYPERTENSION; INTERSTITIAL LUNG DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PNEUMOCYSTOSIS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 85048782972     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2017-000491     Document Type: Article

References (37)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
3. Singh JA, Saag KG, Bridges-Jr SL, et al. American College of Rheumatology Guideline for the treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016;68:1-26.
4. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
5. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
6. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 2016;75:1081-91.
7. Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 2015;74:19-26.
8. Emery P, Fleischmann RM, Moreland L, et al. Golimumab, a human anti-tumor necrosis factor and monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
9. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
10. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35.
11. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Doubleblind randomised controlled trial. Lancet 2004;363:675-81.
12. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
13. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
14. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet 2013;381:451-60.
15. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. Ann Intern Med 2013;159:253-61.
16. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970-81.
17. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690, 550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res 2011;63:1150-8.
18. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70.
19. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
20. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
21. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb doseranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to diseasemodifying antirheumatic drugs. Arthritis Rheum 2012;64:617-29.
22. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum 2009;60:1895-905.
23. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86.
24. Hamann P, Holland R, Hyrich K, et al. Factors associated with sustained remission in rheumatoid arthritis in patients treated with anti-Tumour Necrosis Factor (anti-TNF). Arthritis Care Res 2016.
25. Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:837-52.
26. Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: An open-label, long-term extension study. Arthritis Res Ther 2016;18:34.
27. van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46.
28. van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-39.
29. Buckley F, Finckh A, Huizinga TW, et al. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: A network meta-analysis. J Manag Care Spec Pharm 2015;21:409-23.
30. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACTRAY). Ann Rheum Dis 2013;72:43-50.
31. Burmester G, Charles-Schoemann C, Isaacs J, et al. Tofacitinib, an oral Janus Kinase inhibitor: Safety comparison in patients with rheumatoid arthritis and an inadequate response to nonbiologic or biologic disease modifying anti-rheumatic drugs. Ann Rheum Dis 2013;72:245.
32. Fleischmann R, van Vollenhoven RF, Vencovsky J, et al. Longterm maintenance of certolizumab pegol safety and efficacy, in combination with methotrexate and as monotherapy, in rheumatoid arthritis patients. Rheumatol Ther 2017;4:57-69.
33. Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238-47.
34. Furst DE, Kavanaugh A, Florentinus S, et al. Final 10-year effectiveness and safety results from study DE020: Adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Rheumatology 2015;54:2188-97.
35. Kivitz A, Haraoui B, Kaine J, et al. A safety analysis of tofacitinib 5 mg twice daily administered as monotherapy or in combination with background conventional synthetic DMARDs in a Phase 3 rheumatoid arthritis population. Arthritis Rheumatol 2015;67.
36. Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis 2016;75:831-41.
37. Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: Implications for the rheumatologist. Semin Arthritis Rheum 2016;46:71-80.